Combinations of nucleoside/nucleotide analogues for HIV therapy.

Nucleoside and nucleotide analogues are essential for the design of effective antiretroviral regimens. There are currently many options for the selection of such drug backbones, although not all combinations will display optimal results. The concomitant administration of certain drugs should be avoided due to high rates of toxicity (ddl/d4T, ddl/TDF), antagonism (AZT/d4T, 3TC/FTC) and/or a greater risk of virological failure (ddl/TDF, ABC/TDF). The understanding of the plasmatic and intracellular metabolism of nucleoside/nucleotide analogues is crucial for deciding the optimal posology of each drug and the better dual combinations to be selected. Interferences between the pathways involved into the intracellular activation of some nucleoside/nucleotide analogues may help to understand why certain drug combinations should be avoided.

[1]  M. Saag,et al.  Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. , 2004, JAMA.

[2]  Felipe García,et al.  Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults , 2004, The Lancet.

[3]  A. Ray,et al.  Role of Purine Nucleoside Phosphorylase in Interactions between 2′,3′-Dideoxyinosine and Allopurinol, Ganciclovir, or Tenofovir , 2004, Antimicrobial Agents and Chemotherapy.

[4]  M. Juan,et al.  Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load , 2004, AIDS.

[5]  Ò. Miró,et al.  Mitochondrial Effects of Antiretroviral Therapies in Asymptomatic Patients , 2004, Antiviral therapy.

[6]  P. Frissen,et al.  Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression , 2003, The Lancet.

[7]  Gene D Morse,et al.  Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. , 2003, The New England journal of medicine.

[8]  Victor De Gruttola,et al.  Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. , 2003, The New England journal of medicine.

[9]  J. Rodman,et al.  Metabolism of Tenofovir and Didanosine in Quiescent or Stimulated Human Peripheral Blood Mononuclear Cells , 2003, Pharmacotherapy.

[10]  M. Moroni,et al.  A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients , 2003, AIDS.

[11]  R. Lanier,et al.  Relative Anti‐HIV‐1 Efficacy of Lamivudine and Emtricitabine In Vitro Is Dependent on Cell Type , 2003, Journal of acquired immune deficiency syndromes.

[12]  F. Maggiolo,et al.  Once-A-Day Therapy for HIV Infection: A Controlled, Randomized Study in Antiretroviral-Naive HIV-1-Infected Patients , 2002, Antiviral therapy.

[13]  L. Scott,et al.  Emtricitabine , 2012, Drugs.

[14]  J. Montaner,et al.  Intracellular carbovir triphosphate levels in patients taking abacavir once a day. , 2002, AIDS.

[15]  J. Bilello,et al.  Pharmacodynamics of Abacavir in an In Vitro Hollow-Fiber Model System , 2002, Antimicrobial Agents and Chemotherapy.

[16]  D. Stein,et al.  Phosphorylation of Nucleoside Analog Antiretrovirals: A Review for Clinicians , 2001, Pharmacotherapy.

[17]  R. Bruno,et al.  Comparison of the Plasma Pharmacokinetics of Lamivudine During Twice and Once Daily Administration in Patients with HIV , 2001, Clinical pharmacokinetics.

[18]  R. Pollard.  Didanosine once daily: potential for expanded use , 2000, AIDS.

[19]  M. Chen,et al.  Preliminary experience of adverse drug reactions, tolerability, and efficacy of a once-daily regimen of antiretroviral combination therapy. , 2000, Journal of acquired immune deficiency syndromes.

[20]  S. Staszewski,et al.  A simple, once‐daily dosing regimen for treating HIV‐1 infection in intravenous drug users , 2000, HIV medicine.

[21]  Pier Paolo Pandolfi,et al.  Mitochondrial Basis for Immune Deficiency: Evidence from Purine Nucleoside Phosphorylase–Deficient Mice , 2000 .

[22]  D. Back,et al.  The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. , 1999, AIDS.

[23]  M. Wainberg,et al.  In vitro Selection and Characterization of HIV-1 with Reduced Susceptibility to PMPA , 1998, Antiviral therapy.

[24]  S D Kemp,et al.  Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. , 1995, Science.

[25]  M. Dudley.  Clinical pharmacokinetics of nucleoside antiretroviral agents. , 1995, The Journal of infectious diseases.